Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit

Basit Öğe Kaydı
dc.authorid0000-0002-6839-2632
dc.contributor.authorBal, Öznur
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorDoğan, Mutlu
dc.contributor.authorDurnalı, Ayşe
dc.contributor.authorÜyetürk, Ümmügül
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorArslan, Ülkü Yalçıntaş
dc.date.accessioned2021-06-23T19:54:01Z
dc.date.available2021-06-23T19:54:01Z
dc.date.issued2020
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground Bisphosphonates are the mainstay therapeutic options for prevention of skeletal-related events and generally used for up to 2 years in bone metastatic cancer patients. Aim We aimed to evaluate the long-term outcomes of prolonged (> 2 years) bisphosphonate usage in bone metastatic breast cancer (BMBC) patients. Methods Ninety-nine BMBC patients who had prolonged bisphosphonates were evaluated retrospectively for long-term outcomes and survival rates. Results Median duration of bisphosphonate therapy was 46.8 (24-198) months. Seven patients had bisphosphonate-related adverse events (osteonecrosis of the jaw (ONJ) (n= 6), ONJ and renal failure (n= 1)). Bisphosphonate was switched to another one because of bone metastasis progression in more than one-third of the patients (n= 36, 36.3%). The patients who had bisphosphonate switch therapy had statistically significant longer overall survival (p< 0.01). Neither duration nor type of bisphosphonates had effect on frequency of bisphosphonate-related adverse events. Conclusion Bisphosphonates might be prolonged for more than 2 years in BMBC patients with an acceptable toxicity profile. In addition, bisphosphonates switch therapy should be preferred in those with progressive bone metastasis since it might contribute to better survival despite bisphosphonates could not have been shown to have survival benefit in previous studies.en_US
dc.identifier.doi10.1007/s11845-019-02120-6
dc.identifier.endpage810en_US
dc.identifier.issn0021-1265
dc.identifier.issn1863-4362
dc.identifier.issue3en_US
dc.identifier.pmid31823174en_US
dc.identifier.scopus2-s2.0-85076626398en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage805en_US
dc.identifier.urihttps://doi.org/10.1007/s11845-019-02120-6
dc.identifier.urihttps://hdl.handle.net/20.500.12491/10382
dc.identifier.volume189en_US
dc.identifier.wosWOS:000548664700007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÜyetürk, Ümmügül
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal Of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBisphosphonatesen_US
dc.subjectBreast Canceren_US
dc.subjectBone Metastasisen_US
dc.subjectOsteonecrosis of the Jawen_US
dc.subjectSurvivalen_US
dc.titleLong-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefiten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
oznur-bal.pdf
Boyut:
271.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu